title: Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease.
abstract: The neurotransmitter serotonin (5-HT) has a multifaceted function in the modulation of information processing through the activation of multiple receptor families, including G-protein-coupled receptor subtypes (5-HT1, 5-HT2, 5-HT4-7) and ligand-gated ion channels (5-HT3). The largest population of serotonergic neurons is located in the midbrain, specifically in the raphe nuclei. Although the medial and dorsal raphe nucleus (DRN) share common projecting areas, in the basal ganglia (BG) nuclei serotonergic innervations come mainly from the DRN. The BG are a highly organized network of subcortical nuclei composed of the striatum (caudate and putamen), subthalamic nucleus (STN), internal and external globus pallidus (or entopeduncular nucleus in rodents, GPi/EP and GPe) and substantia nigra (pars compacta, SNc, and pars reticulata, SNr). The BG are part of the cortico-BG-thalamic circuits, which play a role in many functions like motor control, emotion, and cognition and are critically involved in diseases such as Parkinson's disease (PD). This review provides an overview of serotonergic modulation of the BG at the functional level and a discussion of how this interaction may be relevant to treating PD and the motor complications induced by chronic treatment with L-DOPA.
authors.affiliation: Department of Pharmacology, Faculty of Medicine and Dentistry, University of the Basque Country UPV/EHU Leioa, Spain ; Department of Pharmacology, Faculty of Pharmacy, University of the Basque Country UPV/EHU Vitoria-Gasteiz, Spain.
authors.forename: Cristina
authors.initials: C
authors.lastname: Miguelez
authors.affiliation: Department of Pharmacology, Faculty of Medicine and Dentistry, University of the Basque Country UPV/EHU Leioa, Spain.
authors.forename: Teresa
authors.initials: T
authors.lastname: Morera-Herreras
authors.affiliation: Department of Pharmacology, Faculty of Medicine and Dentistry, University of the Basque Country UPV/EHU Leioa, Spain.
authors.forename: Maria
authors.initials: M
authors.lastname: Torrecilla
authors.affiliation: Department of Pharmacology, Faculty of Medicine and Dentistry, University of the Basque Country UPV/EHU Leioa, Spain ; Department of Pharmacology, Faculty of Pharmacy, University of the Basque Country UPV/EHU Vitoria-Gasteiz, Spain.
authors.forename: Jose A
authors.initials: JA
authors.lastname: Ruiz-Ortega
authors.affiliation: Department of Pharmacology, Faculty of Medicine and Dentistry, University of the Basque Country UPV/EHU Leioa, Spain.
authors.forename: Luisa
authors.initials: L
authors.lastname: Ugedo
mesh_terms: D000978:Antiparkinson Agents / Q000627:therapeutic use; D001479:Basal Ganglia / Q000378:metabolism*; D006801:Humans; D009474:Neurons / Q000378:metabolism*; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism*; D012701:Serotonin / Q000378:metabolism*
chemical_list: D000978:Antiparkinson Agents; D012701:Serotonin
keywords: 5-HT; L-DOPA induced dyskinesia; Parkinson's disease; basal ganglia; electrophysiology